Core Viewpoint - Avanos Medical, Inc. has divested its Hyaluronic Acid product line to Channel-Markers Medical, LLC, aligning with its strategic focus on Pain Management & Recovery and Specialty Nutrition Systems [1][3]. Group 1: Transaction Details - The divested portfolio includes TriVisc® and GenVisc® 850 injection products, which are used for treating osteoarthritis pain in the knee [2]. - Ownership of Avanos' HA product line has officially transferred to Channel-Markers Medical, with Avanos providing transition support through the end of 2025 [4]. Group 2: Strategic Implications - This divestiture is a significant step in Avanos' transformation strategy, aimed at reinforcing its commitment to focused growth and aligning its product portfolio with strategic priorities [3]. - Channel-Markers Medical aims to expand its presence in musculoskeletal health and injectable pain therapies through this acquisition [3]. Group 3: Company Profiles - Avanos Medical is a medical technology company focused on delivering clinically superior medical device solutions, addressing healthcare needs such as nutrition and opioid reduction [5]. - Channel-Markers Medical specializes in joint health, regenerative therapies, and minimally invasive pain management solutions, serving various healthcare specialties [6].